First Manhattan CO. LLC. Buys 13,747 Shares of IQVIA Holdings Inc. $IQV

First Manhattan CO. LLC. grew its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 5.4% in the fourth quarter, HoldingsChannel.com reports. The fund owned 268,866 shares of the medical research company’s stock after acquiring an additional 13,747 shares during the quarter. First Manhattan CO. LLC.’s holdings in IQVIA were worth $60,605,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of IQV. Brighton Jones LLC lifted its position in shares of IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after acquiring an additional 2,537 shares during the period. Empowered Funds LLC lifted its position in shares of IQVIA by 102.1% during the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after buying an additional 4,915 shares during the last quarter. Sivia Capital Partners LLC acquired a new stake in IQVIA in the second quarter valued at about $514,000. First Trust Advisors LP grew its position in IQVIA by 14.8% in the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock valued at $14,501,000 after acquiring an additional 11,845 shares during the last quarter. Finally, NewEdge Advisors LLC raised its stake in IQVIA by 5.4% during the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock worth $3,582,000 after acquiring an additional 1,155 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on IQV. HSBC set a $210.00 target price on IQVIA in a research note on Wednesday, June 3rd. TD Cowen raised IQVIA from a “hold” rating to a “buy” rating and boosted their target price for the stock from $174.00 to $213.00 in a research note on Monday, March 9th. Royal Bank Of Canada began coverage on IQVIA in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 target price for the company. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research note on Sunday. Finally, Morgan Stanley reissued an “equal weight” rating and set a $200.00 target price (down from $225.00) on shares of IQVIA in a research note on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $222.56.

IQVIA Stock Performance

NYSE:IQV opened at $170.58 on Thursday. The stock has a market cap of $28.47 billion, a P/E ratio of 21.14, a price-to-earnings-growth ratio of 1.54 and a beta of 1.21. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The stock’s 50-day moving average is $173.77 and its 200-day moving average is $192.26. IQVIA Holdings Inc. has a 1-year low of $153.01 and a 1-year high of $247.04.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.83 by $0.07. The company had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same period in the previous year, the business posted $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities research analysts anticipate that IQVIA Holdings Inc. will post 11.6 earnings per share for the current year.

IQVIA announced that its board has authorized a stock buyback program on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its stock is undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.